NCT06638034View on ClinicalTrials.gov

Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

February 1, 2025

Conditions
FAP- Expressing Positive TumorsRGD- Expressing Positive Tumors
Interventions
DRUG

68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy

Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.

Trial Locations (1)

100730

RECRUITING

Chinese Academy of Medical Science & Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER